Premium
Hyperinsulinaemic hypoglycaemia: genetic mechanisms, diagnosis and management
Author(s) -
Senniappan Senthil,
Shanti Balasubramaniam,
James Chela,
Hussain Khalid
Publication year - 2012
Publication title -
journal of inherited metabolic disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.462
H-Index - 102
eISSN - 1573-2665
pISSN - 0141-8955
DOI - 10.1007/s10545-011-9441-2
Subject(s) - human genetics , medicine , genetic testing , genetic diagnosis , genetics , bioinformatics , intensive care medicine , biology , gene
Hyperinsulinaemic hypoglycaemia (HH) is due to the unregulated secretion of insulin from pancreatic β‐cells. A rapid diagnosis and appropriate management of these patients is essential to prevent the potentially associated complications like epilepsy, cerebral palsy and neurological impairment. The molecular basis of HH involves defects in key genes ( ABCC8, KCNJ11, GLUD1, GCK, HADH, SLC16A1, HNF4A and UCP2 ) which regulate insulin secretion. The most severe forms of HH are due to loss of function mutations in ABCC8/KCNJ11 which encode the SUR1 and KIR6.2 components respectively of the pancreatic β‐cell K ATP channel. At a histological level there are two major forms (diffuse and focal) each with a different genetic aetiology. The diffuse form is inherited in an autosomal recessive (or dominant) manner whereas the focal form is sporadic in inheritance and is localised to a small region of the pancreas. The focal form can now be accurately localised pre‐operatively using a specialised positron emission tomography scan with the isotope Fluroine‐18L‐3, 4‐dihydroxyphenyalanine (18F‐DOPA‐PET). Focal lesionectomy can provide cure from the hypoglycaemia. However the diffuse form is managed medically or by near total pancreatectomy (with high risk of diabetes mellitus). Recent advances in molecular genetics, imaging with 18F‐DOPA‐PET/CT and novel surgical techniques have changed the clinical approach to patients with HH.